August 14, 2017 / 12:22 PM / a year ago

BRIEF-Critical Outcome Technologies completes phase 1 dose escalation portion of COTI-2 trial

Aug 14 (Reuters) - Critical Outcome Technologies Inc

* Critical Outcome Technologies completes phase 1 dose escalation portion of COTI-2 trial in gynecological malignancies

* Has initiated an expansion arm of its phase 1 study in patients with head and neck squamous cell carcinoma​

* Company expects top-line data from head and neck squamous cell carcinoma expansion arm in 2018 ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below